Viking soars on positive early data in the obesity space

29 March 2023
viking_therapeutics_company

US clinical-stage biopharma company Viking Therapeutics (Nasdaq: VKTX) saw its shares close up nearly 70% at $15.44 yesterday, after it released encouraging early-stage data on its obesity candidate VK2735.

The compound is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders. Based on these Phase I results, the company plans to initiate a Phase II study of VK2735 in patients with obesity in mid-2023.

Depending on the success of the drug in upcoming studies, Viking would compete in a potential $50 billion market for obesity treatment, with industry heavyweights such as Eli Lilly (NYSE: LLY) and Novo Nordisk (NOV: N).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical